









**A** TCGA pan-cancer analysis**B** TCGA-SKCM**C** TCGA-SKCM TIDE prediction**D** TCGA-SKCM TIDE prediction**E** TCGA-SKCM All**F** TCGA-SKCM TGFB1-low (below median)

Patients


**F** TCGA-SKCM TGFB1-high (above median)

**Supplementary Figure 1. The association of YTHDF1 expression with immune cell infiltration and the response to ICI therapy.** (A) Spearman correlation of *YTHDF1* expression with the immune score. RNA-seq data from a total of 10363 individuals in the TCGA, representing 33 different types of tumors, were examined. (B) Heatmap presenting immune cell infiltration in the *YTHDF1*-high and *YTHDF1*-low groups. The standard used to define high and low *YTHDF1* expression was determined based on median *YTHDF1* expression. ssGSEA was performed to estimate the infiltration of 28 immune cell types according to the summarized immune gene signature. (C) Box plot showing the differential expression of *YTHDF1* in the responder (n = 100 biologically independent samples) and nonresponder (n = 370 biologically independent samples) groups using RNA-sequencing data from the TCGA-SKCM dataset. Tumor immune dysfunction and exclusion (TIDE) analysis was conducted to predict the ICI response. TIDE (<http://tide.dfci.harvard.edu/>) is an analytic technique that enables the prediction of the ICI response. The upper, middle and lower horizontal lines of the box represent the upper, median and lower quartile respectively. Whiskers depict the smallest or largest values within 1.5-fold of the interquartile range, and the points outside the box represent outliers. Two-tailed Wilcoxon test. (D) A waterfall plot showing *YTHDF1* expression (z-score) for responders and nonresponders in the TCGA-SKCM dataset. (E, F) Prognostic value of *YTHDF1* in the TCGA-SKCM dataset (E) and its subgroup analysis in *TGFB*-high and *TGFB*-low groups (F). Two-tailed log-rank (Mantel-Cox) test. Source data are provided as a Source Data file.


A




B




C




D




E



F




**Supplementary Figure 2. The association of m6A regulator expression with the ICI response.** (A-C) Box plot showing the expression of m6A readers (A), writers (B), and erasers (C) in the PD and CR groups using RNA-sequencing data from the Hugo2016\_PD1\_Melanoma cohort (n = 18 biologically independent samples). (D-F) Box plot showing the expression of m6A readers (D), writers (E), and erasers (F) in the PD, SD, and PR/CR groups using RNA-sequencing data from the Riaz2016\_PD1\_Melanoma cohort (n = 56 biologically independent samples). The upper, middle and lower horizontal lines of the box represent the upper, median and lower quartile respectively. Whiskers depict the smallest or largest values within 1.5-fold of the interquartile range, and the points outside the box represent outliers. Two-tailed unpaired Student's *t* test (A-C) and Kruskal-Wallis with Dunn's multiple comparison test (D-F) are reported. Source data are provided as a Source Data file.




**Supplementary Figure 3. Establishment and validation of CRISPR/Cas9-mediated *Ythdf1* knockout cell clones.** (A) Fragment knockout strategy for *Ythdf1* depletion. (B) Structure of the *Ythdf1* KO plasmid. (C) Workflow for the generation of *Ythdf1* knockout cell clones. WT cells were exposed to the same procedure as KO cells except for transfection with the scramble plasmid. (D-F) Validation of *Ythdf1* depletion by Sanger sequencing (D), PCR (E), and western blotting (F). One of two representative experiments with similar results is shown. (G) Cell viability (n = 3 biologically independent samples per group). Two-tailed unpaired Student's *t* test. Data are presented as mean values +/- SD. (H) Cell growth (n = 3 biologically independent samples per group). Two-tailed unpaired Student's *t* test. Data are presented as mean values +/- SD. (I) Clonogenic assay (n = 3 biologically independent samples per group). Two-tailed unpaired Student's *t* test. Data are presented as mean values +/- SD. (J) Visualization of DNA replication by EdU incorporation (n = 3 biologically independent samples per group). Blue = DAPI, and red = EdU. Scale bar, 50  $\mu$ m. Two-tailed unpaired Student's *t* test. Data are presented as mean values +/- SD. P values were determined using a two-tailed Student's *t* test (NS  $P > 0.05$ ). Source data are provided as a Source Data file.

A




B

Heat map of differential immune genes




C

Lung metastases




D




Subcutaneous tumors











**Supplementary Figure 4. Identification of differentially expressed immune-relevant genes and tumor-infiltrating T cells.** (A) Venn diagram presenting the overlap of differentially expressed genes and immune-relevant genes. The immune-relevant gene list was obtained from the ImmPort database (<https://www.immport.org/shared/genelists>). (B) Heatmap of overlapping genes. Among the 140 overlapping immune-relevant genes, 133 were upregulated while 7 were downregulated in *Ythdf1*-KO tumors inoculated in C57BL/6J mice (n = 6 per group). (C, D) Immunohistochemical staining for CD4<sup>+</sup> and CD8<sup>+</sup> T cells in B16/F10 lung metastases (C) and subcutaneous tumors (D). Scale bar, 100 μm. One of two representative experiments with similar results is shown. Source data are provided as a Source Data file.



**Supplementary Figure 5. scRNA-seq analysis of CD4<sup>+</sup> T-cell subpopulations.** (A) Heatmap of differentially expressed genes in each CD4<sup>+</sup> T-cell cluster. (B) Marker gene expression for each CD4<sup>+</sup> T-cell immune subpopulation, with dot color and size representing the averaged scaled expression (avg. exp. scale) value and percentage of marker gene expression (pct. exp), respectively. (C) t-SNE view of Tregs, color-coded by the indicated marker gene abundance. (D) Pseudotime analysis with dark blue indicating the starting point, the arrow denoting the trajectory across pseudotime and light blue representing the end of pseudotime. (E, F) Differentiation trajectories of cell clusters, color coded by cell cluster (E) and sample group (F). (G) Differential gene expression analysis showing up- and downregulated genes across all five CD4<sup>+</sup> T-cell subpopulations. (H) Gene ontology (GO) biological process (BP) enrichment for proliferating CD4<sup>+</sup> T cells and CD4<sup>+</sup> effector memory T cells (CD4 TEMs). Genes upregulated in the *Ythdf1*-KO group were collected for enrichment analysis. The one-tailed Fisher Exact test is reported. Source data are provided as a Source Data file.




**Supplementary Figure 6. scRNA-seq analysis of CD8<sup>+</sup> T-cell subpopulations.** (A) Heatmap of differentially expressed genes in each CD8<sup>+</sup> T-cell cluster. (B) Marker gene expression for each CD8<sup>+</sup> T-cell immune subpopulation, with dot color and size representing the averaged scaled expression (avg. exp. scale) value and percentage of marker gene expression (pct. exp), respectively. (C) Differential gene expression analysis showing up- and down-regulated genes across all four CD8<sup>+</sup> T-cell subpopulations. (D) GO biological process enrichment for CD8<sup>+</sup> effector memory T cells (CD8<sup>+</sup> TEMs) and exhausted CD8<sup>+</sup> T cells (CD8<sup>+</sup> TEXs). Genes upregulated in the *Ythdf1*-KO group were collected for enrichment analysis. The one-tailed Fisher Exact test is reported. Source data are provided as a Source Data file.




**Supplementary Figure 7. scRNA-seq analysis of neutrophil subpopulations.** (A) t-SNE view of neutrophil markers, color coded by the indicated marker gene abundance. (B) t-SNE plot of neutrophil subpopulations, color coded by cell cluster. (C) Marker gene expression for each neutrophil subpopulation, with dot color and size representing the averaged scaled expression (avg. exp. scale) value and percentage of marker gene expression (pct. exp), respectively. (D) Heatmap of the cell count for each neutrophil subpopulation. (E) t-SNE view of neutrophils, color coded by the tumor-promoting genes abundance. (F) Violin plot of *Fabp5* expression for each neutrophil subpopulation. (G) Kaplan–Meier OS curve for melanoma patients with high or low FABP5 expression using RNA-sequencing data from the TCGA and GEO databases. Two-sided log-rank test. Source data are provided as a Source Data file.


A




B







C



D




**Supplementary Figure 8. scRNA-seq analysis of B cells.** (A) t-SNE plot of B-cells subpopulations, color coded by sample group, and bar plot depicting the ratios of B cells in WT and *Ythdf1*-KO tumors. (B) t-SNE view of naive B-cell markers (*Cd19*, *Ighd*, and *Cd20*), color coded by the indicated marker gene abundance. (C) t-SNE view of activated B-cell markers (*Cd25* and *Cd30*), plasma cell markers (*Ighg1* and *Cd27*), or memory B-cell markers (*Cd27*, *Igha*, and *Ighg1*), color coded by the indicated marker gene abundance. (D) t-SNE plot of immunosuppressive molecules (*Cd274* and *Tgfb1*), color coded by the indicated marker gene abundance. Source data are provided as a Source Data file.





**Supplementary Figure 9. m6A MeRIP-seq, eCLIP-seq, and ribo-seq analysis.** (A) The distribution of m6A peak reads and proportions in the 5'UTR, start codon, CDS, stop codon and 3'UTR in mRNA transcripts. (B) The m6A motif detected by MEME motif analysis. The RRACH and DRACH (D=G/A/U, R=G/A, H=A/U/C) conserved sequence motifs for m6A-containing peak regions. (C) Overlap of YTHDF1-binding transcripts revealed from eCLIP-seq of two biological replicates. (D) The distribution and percentage of ribosome-protected transcripts in the coding, 5'UTR, 3'UTR, and intronic regions. (E) Bar plot illustrating the count of each ribosome-protected fragment, with colors representing different frames. (F) Quantitative estimates of cell surface MHC-II levels in WT and *Ythdf1*-KO B16F10 cells (n = 3 biologically independent samples per group). Two-tailed unpaired Student's *t* test. Data are presented as mean values +/- SD. Source data are provided as a Source Data file.




**Supplementary Figure 10. Toxicity test of engineered exosomes treatment.** (A) Body weight ( n = 5 biologically independent samples per group). Two-tailed unpaired Student's *t* test. Data are presented as mean values +/- SD. (B) HE staining of liver, lung, and kidney tissue. Scale bar, 200 μm. One of three representative experiments with similar results is shown. (C) Evaluation of blood biochemistry, including albumin (ALB), alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), total bile acid (TBA), creatinine (Crea), Urea, cholesterol (CHOL), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglyceride (TG), creatine kinase (CK), Creatine kinase MB isoenzyme (CK-MB), lactic dehydrogenase (LDH), glucose (GLU), and glycated serum protein (GSP). n = 3 biologically independent samples per group. Two-tailed unpaired Student's *t* test. Data are presented as mean values +/- SD. Source data are provided as a Source Data file.



**Supplementary Figure 11.** Gating strategy of tumor-infiltrating CD4<sup>+</sup> and CD8<sup>+</sup> T cells.

**A**Gating strategy of CD45<sup>+</sup> cell FACS sorting in WT groups**B**Gating strategy of CD45<sup>+</sup> cell FACS sorting in KO groups**C**

## Blank control



**Supplementary Figure 12. Flow-sorting of CD45<sup>+</sup> cells from tumor tissue. (A-C)**  
Gating strategy of flow-sorting in WT, KO and blank control groups.